Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mutationally activated BRAF is a key driver in various cancers.
• The RAF family of protein kinases plays a critical role in oncogenesis.
• BRAF mutations have reshaped the understanding of cancer development.

Purpose of the Study:

• To review the development and clinical analysis of BRAF inhibitors.
• To discuss the spectrum of RAF mutations in human cancers.
• To explore mechanisms of resistance and future strategies for RAF pathway inhibition.

Main Methods:

• Literature review of BRAF inhibitors in laboratory and clinical settings.
• Analysis of RAF mutation spectrum across different human malignancies.
• Characterization of resistance mechanisms to BRAF inhibition.

Main Results:

• BRAF inhibitors have emerged as a significant therapeutic strategy.
• The response to RAF inhibition is complex and influenced by tissue of origin.
• Various mechanisms of resistance to BRAF inhibitors have been identified.

Conclusions:

• BRAF inhibitors offer therapeutic benefits for BRAF-mutated cancers, notably metastatic melanoma.
• Understanding RAF mutation interplay and resistance is crucial for optimizing treatment.
• Expanding RAF pathway inhibition strategies may benefit a larger patient population with RAF-driven malignancies.